One of the largest studies involving Ivermectin, the drug that was being administered worldwide to treat Covid patients, has been withdrawn amid concerns of plagiarism and problems with their raw data.
Editor-in-chief of Research Square, said the study was retracted on July 14, after they were given evidence of both plagiarism and anomalies in the data set associated with the study. The study has been included in two recent meta-analyses that received much attention for their positive results.
A team from University of Liverpool in England, which conducted a randomised controlled trial from samples in Argentina, found no role of Ivermectin in preventing hospitalization in patients with Covid-19. It also found that those who received Ivermectin required invasive ventilation sooner than those on placebo.
Also watch | Bharat Biotech terminates MoU with Brazilian partners amid corruption allegations